According to SPER Market Research, the Biomarkers Market is estimated to reach USD 117.6 billion by 2030 with a CAGR of 11.8%. Companion diagnostics, growing incidence of cancer globally, escalating funds & grants for biomarker research, and persistent innovations; these are the key factors acting as the fuel for the expansion of this market.
Biomarker validation, expensive method, biomarker development a time consuming process, methodological issues associated with sample collection & storage; are the challenges to this market.
Biomarkers, with the capability to spot drug target molecules play an important function in the development of companion diagnostics and personalized medicine, due to the growing demand for personalized medicine; market players in this provide huge opportunities.
North America owns the prime share of this market; it is due to the implementation of biomarkers in the diagnosis of diseases like cancer diagnosis, rising exploitation of biomarkers in personalized medicine, presence of big pharmaceutical companies, and adoption of strategies for the escalation of the market.
The global Biomarkers Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Abbott Laboratories, Bio-Rad Laboratories, Inc., Charles River Laboratories, International, Inc., Enzo Biochem, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for Product segment- Consumables, Services, Software, for Type segment-Efficacy Biomarkers, Pharmacodynamics Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Biomarkers, Validation Biomarkers, for Application segment- Diagnostics, Disease Risk Assessment, Drug Discovery & Development, Other Applications, Personalized Medicine, for Disease Indication segment-Cancer by Test Type (Solid biopsy, Liquid Biopsy), Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders.
This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.